Presbyopia Solution Target ophthalmology practices and clinics that perform refractive and corneal surgeries to introduce Raindrop Near Vision Inlay as a patient option for presbyopia, focusing on surgeons and coordinators seeking premium, innovative corneal solutions.

FDA-Approved Advantage Highlight the product’s FDA approval and global availability to establish credibility with procurement teams and compliance officers, positioning ReVision Optics as a regulated, proven option in the near vision market.

Growth Momentum Leverage the historical funding and commercialization push to engage potential distributors and private clinics, emphasizing strong backing and ongoing support for market expansion in North America and beyond.

Clinical Risk Profile Provide clear, balanced materials on benefits and potential risks, enabling sales teams to address patient selection criteria, contraindications, and aftercare, thereby supporting informed adoption and minimizing post-installation issues.

Market Positioning Position Raindrop as a first-inlay option that reshapes corneal tissue to reduce reading dependence, targeting eye banks, clinics, and optical retailers looking to differentiate their offerings with cutting-edge presbyopia therapies.